Study determines critical skills for PCPs to safely manage opioid risk in chronic pain patients

 

  • The study’s objective was to identify which skills and competencies are considered most critical for primary care providers (PCPs) to learn in order to effectively manage opioid risk in patients treated for chronic pain
  • Study participants included experts in primary care, pain management, and addiction
  • Experts in this study identified the most important skills for PCPs managing opioid risk in chronic pain patients as how to monitor opioids and how to assess for risk factors

 

Newton, MA, USA (March 16, 2012) – Primary care physicians are faced with treating a large proportion of chronic pain patients, but many do not often have specific training in the assessment and management of chronic pain, including the use of opioid medications for chronic pain management. Recognizing the significant role prescribers can play in reducing the risk of addiction, unintentional overdose, and death from the misuse and abuse of opioids, the U.S. Food and Drug Administration (FDA) has made prescriber education a central part of its Risk Evaluation and Mitigation Strategy (REMS) requirements for manufacturers of long-acting and extended-release (LA/ER) opioids.

 

With this in mind, Inflexxion’s study investigated 1) what skills and training are considered to be needed for PCPs to prescribe opioids safely and effectively to patients with chronic pain, 2) what education would physicians find most relevant to clinical practice, and 3) what would resonate with them most.

 

The full report of this study, "Identifying Primary Care Skills and Competencies in Opioid Risk Management" was published in the Fall 2011 issue of The Journal of Continuing Education in the Health Professions.

 

Inflexxion researchers interviewed a panel of 16 nationally-known experts in primary care, pain management, and addiction about the knowledge and competencies they believed were most important for treating chronic pain safely and effectively in a primary care setting. Their responses were collated and analyzed using an online concept mapping program, which offers an innovative method of summarizing and prioritizing qualitative data.

 

Results showed the impressions of what skills PCPs thought their colleagues needed most, and those that pain and addiction specialists believed PCPs should have, diverged. While both groups agreed that the most important area for education was how to manage pain patients with comorbid conditions, PCPs were more concerned that their peers learn things like understanding aberrant drug-related behavior, how to monitor compliance to therapy, and how to ensure safe and appropriate prescribing of opioids than the specialists. Specialists placed greater emphasis on PCPs learning how to formulate a treatment plan, having a general understanding of chronic pain management, and being able to teach medication safety to patients.

 

"Primary care physicians treat a high proportion of chronic pain patients but often lack training about how to assess and address issues associated with prescribing opioids when they are an appropriate component of therapy. The result may be that they could avoid treating these patients, which can lead to an under treatment of pain," says Kevin Zacharoff, MD, Vice President of Medical Affairs for Inflexxion and co-author of this study. "As pharmaceutical manufacturers and educators move forward on developing educational programs with the goal of meeting FDA concerns about the safe use of opioids, understanding the skills and competencies needed in primary care can have a tremendous positive impact on public health."

 

 

Inflexxion received funding from the National Institute of Drug Abuse (NIDA) to conduct this study.

 

 

About Inflexxion

 

Inflexxion develops scientifically-based, interactive technologies that help people improve their lives through behavioral change. Partners and customers rely on Inflexxion for online programs that reduce health-related risks, enhance clinical outcomes, and positively influence quality of care. Inflexxion has received over $64 million in grant support from the National Institutes of Health (NIH) and Small Business Innovation Research Program (SBIR), and has developed over 50 assessment, intervention and prevention programs in its behavioral health, risk management, college health, and consumer health divisions. Located in Newton, MA and founded in 1989, Inflexxion has over 90 employees.

 


 

Inflexxion, 16.03.2012 (tB).

MEDICAL NEWS

COVID-19 vaccines are estimated to have prevanented 20 million deaths…
Novel sleep education learning modules developed for nurse practitioners
Inadequate sequencing of SARS-CoV-2 variants impedes global response to COVID-19
New meta-analysis finds cannabis may be linked to development of…
New guidance on how to diagnosis and manage osteoporosis in…

SCHMERZ PAINCARE

Aktuelle Versorgungssituation der Opioidtherapie im Fokus
Individuelle Schmerztherapie mit Opioiden: Patienten im Mittelpunkt
Versorgung verbessern: Deutsche Gesellschaft für Schmerzmedizin fordert die Einführung des…
Pflegeexpertise im Fokus: Schmerzmanagement nach Operationen
Versorgung verbessern: Bundesweite Initiative der Deutschen Gesellschaft für Schmerzmedizin zu…

DIABETES

Typ-1-Diabetes: InRange – auf die Zeit im Zielbereich kommt es…
Suliqua®: In komplexem Umfeld – einfach besser eingestellt
Suliqua®: Überlegene HbA1c-Senkung  im Vergleich zu Mischinsulinanalogon
„Wissen was bei Diabetes zählt: Gesünder unter 7 PLUS“ gibt…
Toujeo® bei Typ-1-Diabetes: Weniger schwere Hypoglykämien und weniger Ketoazidosen 

ERNÄHRUNG

Mangelernährung gefährdet den Behandlungserfolg — DGEM: Ernährungsscreening sollte zur klinischen…
Wie eine Diät die Darmflora beeinflusst: Krankenhauskeim spielt wichtige Rolle…
DGEM plädiert für Screening und frühzeitige Aufbautherapie: Stationäre COVID-19-Patienten oft…
Führt eine vegane Ernährungsweise zu einer geringeren Knochengesundheit?
Regelmässiger Koffeinkonsum verändert Hirnstrukturen

ONKOLOGIE

Krebspatienten unter Immuntherapie: Kein Hinweis auf erhöhtes Risiko für schwere…
WHO veröffentlicht erste Klassifikation von Tumoren im Kindesalter
Anti-Myelom-Therapie mit zusätzlich Daratumumab noch effektiver
Positive Ergebnisse beim fortgeschrittenen Prostatakarzinom: Phase-III-Studie zur Radioligandentherapie mit 177Lu-PSMA-617
Lymphom-News vom EHA2021 Virtual. Alle Berichte sind nun online verfügbar!

MULTIPLE SKLEROSE

Multiple Sklerose durch das Epstein-Barr-Virus – kommt die MS-Impfung?
Neuer Therapieansatz für Multiple Sklerose und Alzheimer
„Ich messe meine Multiple Sklerose selbst!“ – Digitales Selbstmonitoring der…
Stellungnahme zur 3. Impfung gegen SARS-CoV2 bei Personen mit MS
NMOSD-Erkrankungen: Zulassung von Satralizumab zur Behandlung von Jugendlichen und Erwachsenen

PARKINSON

Alexa, bekomme ich Parkinson?
Meilenstein in der Parkinson-Frühdiagnose
Parkinson-Erkrankte besonders stark von Covid-19 betroffen
Gangstörungen durch Kleinhirnschädigung beim atypischen Parkinson-Syndrom
Parkinson-Agenda 2030: Die kommenden 10 Jahre sind für die therapeutische…